KR20050044600A - [1,2,4]-트리아졸 바이사이클릭 아데노신 A2a 수용체길항제 - Google Patents

[1,2,4]-트리아졸 바이사이클릭 아데노신 A2a 수용체길항제 Download PDF

Info

Publication number
KR20050044600A
KR20050044600A KR1020047007953A KR20047007953A KR20050044600A KR 20050044600 A KR20050044600 A KR 20050044600A KR 1020047007953 A KR1020047007953 A KR 1020047007953A KR 20047007953 A KR20047007953 A KR 20047007953A KR 20050044600 A KR20050044600 A KR 20050044600A
Authority
KR
South Korea
Prior art keywords
alkyl
mmol
compound
alkoxy
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020047007953A
Other languages
English (en)
Korean (ko)
Inventor
뉴스타트버나드알.
리우홍
Original Assignee
쉐링 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쉐링 코포레이션 filed Critical 쉐링 코포레이션
Publication of KR20050044600A publication Critical patent/KR20050044600A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020047007953A 2001-11-30 2002-11-26 [1,2,4]-트리아졸 바이사이클릭 아데노신 A2a 수용체길항제 Withdrawn KR20050044600A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33438501P 2001-11-30 2001-11-30
US60/334,385 2001-11-30

Publications (1)

Publication Number Publication Date
KR20050044600A true KR20050044600A (ko) 2005-05-12

Family

ID=23306955

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047007953A Withdrawn KR20050044600A (ko) 2001-11-30 2002-11-26 [1,2,4]-트리아졸 바이사이클릭 아데노신 A2a 수용체길항제

Country Status (18)

Country Link
US (2) US6875772B2 (cg-RX-API-DMAC7.html)
EP (1) EP1453836B1 (cg-RX-API-DMAC7.html)
JP (2) JP4429724B2 (cg-RX-API-DMAC7.html)
KR (1) KR20050044600A (cg-RX-API-DMAC7.html)
CN (1) CN1688581A (cg-RX-API-DMAC7.html)
AR (1) AR037681A1 (cg-RX-API-DMAC7.html)
AT (1) ATE358130T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002352933A1 (cg-RX-API-DMAC7.html)
CA (1) CA2468658C (cg-RX-API-DMAC7.html)
DE (1) DE60219196T2 (cg-RX-API-DMAC7.html)
ES (1) ES2283625T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0402324A3 (cg-RX-API-DMAC7.html)
IL (1) IL161573A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04005158A (cg-RX-API-DMAC7.html)
PE (1) PE20030653A1 (cg-RX-API-DMAC7.html)
TW (1) TW200300689A (cg-RX-API-DMAC7.html)
WO (1) WO2003048163A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200404168B (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210025609A (ko) * 2018-06-26 2021-03-09 쩌지앙 빔그린 파머슈티컬스, 엘티디 A2a 수용체 길항제로서의 트리아졸로 트리아진 유도체
KR20220146348A (ko) * 2021-04-23 2022-11-01 주식회사 종근당 아데노신 A2a 수용체 길항제로서의 화합물 및 이를 포함하는 약학적 조성물

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200300686A (en) 2001-11-30 2003-06-16 Schering Corp Adenosine A2a receptor antagonists
CA2468658C (en) * 2001-11-30 2009-04-14 Schering Corporation [1,2,4]-triazole bicyclic adenosine a2a receptor antagonists
CN101492383A (zh) * 2002-03-12 2009-07-29 惠氏公司 制备手性1,4-二取代哌嗪的方法
AU2003272886A1 (en) * 2002-09-24 2004-04-19 Kyowa Hakko Kogyo Co., Ltd. (1,2,4)-TRIAZOLO(1,5-c)PYRIMIDINE DERIVATIVE
MXPA05006790A (es) 2002-12-19 2005-09-08 Schering Corp Usos de antagonistas del receptor adenosina a2a.
WO2004092170A2 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolotriazines and pyrazolotriazines useful as a2a adenosine receptor antagon ists
EP1633756B1 (en) 2003-04-09 2008-12-24 Biogen Idec MA Inc. A2a adenosine receptor antagonists
EP1615931A1 (en) 2003-04-09 2006-01-18 Biogen Idec MA Inc. Triazolopyrazines and methods of making and using the same
EP1618109A2 (en) * 2003-04-09 2006-01-25 Biogen Idec MA Inc. Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists
TW200507850A (en) 2003-07-25 2005-03-01 Kyowa Hakko Kogyo Kk Pharmaceutical composition
WO2006129626A1 (ja) * 2005-05-30 2006-12-07 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]トリアゾロ[1,5-c]ピリミジン誘導体の製造法
JPWO2006132275A1 (ja) 2005-06-07 2009-01-08 協和醗酵工業株式会社 運動障害の予防および/または治療剤
EP1896415A1 (en) * 2005-06-08 2008-03-12 NeuroSearch A/S Novel n-phenyl-piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
TW200803856A (en) 2005-09-02 2008-01-16 Mount Cook Biosciences Inc Method of treating parkinson's disease with diarylmethylpiperazine compounds exhibiting delta receptor agonist activity
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
US7615556B2 (en) * 2006-01-27 2009-11-10 Bristol-Myers Squibb Company Piperazinyl derivatives as modulators of chemokine receptor activity
US20110064671A1 (en) 2008-03-10 2011-03-17 Cornell University Modulation of blood brain barrier permeability
WO2010008775A1 (en) * 2008-06-23 2010-01-21 Ligand Pharmaceuticals Inc. Aminopyridopyrazinone derivatives for treating neurodegenerative diseases
GB201214106D0 (en) * 2012-08-07 2012-09-19 Univ Strathclyde Immunomodulatory compounds
EP3436013A4 (en) 2016-03-31 2019-11-13 Versi Group, LLC DELTA OPIOID AGONIST, MU OPIOID ANTAGONIST COMPOSITIONS AND METHOD FOR TREATING MORBUS PARKINSON
CN106866582A (zh) * 2017-01-10 2017-06-20 广州隽沐生物科技有限公司 一种氟班色林中间体的制备方法
US12325708B2 (en) 2019-05-03 2025-06-10 Nektar Therapeutics Adenosine 2 receptor antagonists
EP4083044A4 (en) * 2019-12-26 2024-03-27 Zhejiang Vimgreen Pharmaceuticals, Ltd USE OF TRIAZOLOTRIAZINE DERIVATIVES TO TREAT DISEASES

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
US5565460A (en) * 1993-07-27 1996-10-15 Kyowa Hakko Koygo Co., Ltd. Therapeutic purine agents for parkinson's disease
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
WO1998042711A1 (en) * 1997-03-24 1998-10-01 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
AU2639299A (en) 1998-02-24 1999-09-15 Kyowa Hakko Kogyo Co. Ltd. Remedies/preventives for parkinson's disease
KR20010087361A (ko) * 1998-09-22 2001-09-15 히라타 다다시 [1,2,4]트리아졸로[1,5-c]피리미딘 유도체
US6355653B1 (en) 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
JP2002037787A (ja) * 2000-05-16 2002-02-06 Kyowa Hakko Kogyo Co Ltd [1,2,4]トリアゾロ[1,5−c]ピリミジン誘導体の製造法
PT1283839E (pt) 2000-05-26 2005-08-31 Schering Corp Antagonistas do receptor a2a da adenosina
JP4545437B2 (ja) * 2001-10-15 2010-09-15 シェーリング コーポレイション アデノシンa2a受容体アンタゴニストとしてのイミダゾ(4,3−e)−1,2,4−トリアゾロ(1,5−c)ピリミジン
CA2468658C (en) * 2001-11-30 2009-04-14 Schering Corporation [1,2,4]-triazole bicyclic adenosine a2a receptor antagonists

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210025609A (ko) * 2018-06-26 2021-03-09 쩌지앙 빔그린 파머슈티컬스, 엘티디 A2a 수용체 길항제로서의 트리아졸로 트리아진 유도체
US11858942B2 (en) 2018-06-26 2024-01-02 Zhejiang Vimgreen Pharmaceuticals, Ltd. Triazolotriazine derivatives as A2A receptor antagonists
KR20220146348A (ko) * 2021-04-23 2022-11-01 주식회사 종근당 아데노신 A2a 수용체 길항제로서의 화합물 및 이를 포함하는 약학적 조성물

Also Published As

Publication number Publication date
CN1688581A (zh) 2005-10-26
EP1453836B1 (en) 2007-03-28
HUP0402324A2 (hu) 2005-02-28
EP1453836A1 (en) 2004-09-08
MXPA04005158A (es) 2004-08-11
HUP0402324A3 (en) 2008-09-29
DE60219196D1 (de) 2007-05-10
PE20030653A1 (es) 2003-08-04
ES2283625T3 (es) 2007-11-01
US7078408B2 (en) 2006-07-18
DE60219196T2 (de) 2008-01-03
US6875772B2 (en) 2005-04-05
JP2010018634A (ja) 2010-01-28
JP4429724B2 (ja) 2010-03-10
US20030191130A1 (en) 2003-10-09
US20050113380A1 (en) 2005-05-26
AR037681A1 (es) 2004-12-01
TW200300689A (en) 2003-06-16
HK1064097A1 (en) 2005-01-21
ATE358130T1 (de) 2007-04-15
CA2468658C (en) 2009-04-14
AU2002352933A1 (en) 2003-06-17
IL161573A0 (en) 2004-09-27
WO2003048163A1 (en) 2003-06-12
CA2468658A1 (en) 2003-06-12
JP2005511697A (ja) 2005-04-28
ZA200404168B (en) 2005-09-02

Similar Documents

Publication Publication Date Title
EP1453836B1 (en) BICYCLIC [1,2,4] -TRIAZOLE ADENOSINE A2a RECEPTOR ANTAGONISTS
US6653315B2 (en) Adenosine A2a receptor antagonists
KR100520907B1 (ko) 아데노신 A2a수용체 길항제
JP4284182B2 (ja) アデノシンA2aレセプターアンタゴニスト
KR20050044607A (ko) 아데노신 A2a 수용체 길항제
AU2002340184A1 (en) Imidazo (4,3-E)-1,2,4-triazolo(1,5-C) pyrimidines as adenosine A2A receptor antagonists
HK1064097B (en) Bicyclic [1,2,4] -triazole adenosine a2a receptor antagonists

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20040525

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid